Home > Haematology > EHA 2021 > Leukaemia > Favourable outcomes with zanubrutinib versus ibrutinib in patients with r/r CLL

Favourable outcomes with zanubrutinib versus ibrutinib in patients with r/r CLL

Presented By
Prof. Peter Hillmen, University of Leeds, UK
Conference
EHA 2021
Trial
Phase 3, ALPINE
Interim results of the ALPINE study suggest that zanubrutinib exhibits superior efficacy and safety in patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) compared with ibrutinib. Treatment of chronic CLL/SLL has been transformed with the advent of effective inhibitors of B-cell receptor signalling, such as Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib. Zanubrutinib is a potent, next-generation BTK inhibitor designed to maximise BTK occupancy and minimise off-target effects, which might minimise toxicities and improve efficacy compared with ibrutinib [1]. The phase 3, randomised ALPINE study (NCT03734016) compared zanubrutinib with ibrutinib in patients with relapsed or refractory (r/r) CLL or SLL with ≥1 prior lines of treatment and measurable lymphadenopathy....


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on